ViiV deal for HIV prevention shot runs into criticism; an investigation into a health data powerhouse

Taking stock of the drug industry, from the lab to the medicine chest ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ 

Sponsored by     STAT+: A ViiV deal to license its HIV prevention shot to poor countries runs into criticism By Ed Silverman NIAID/NIH Advocacy groups argue the deal could have limited impact due to manufacturing restrictions and pricing uncertainties. Read More STAT+: Internal documents show privacy lapses at a data powerhouse that holds health records and consumer information on millions of Americans By Casey Ross Casey Shenery for STAT A STAT investigation found privacy lapses in IQVIA's secretive and long-running data relationship with Experian. Read More Opinion: STAT+: How to close biopharma's data science and engineering skills gap By Sajith Wickramasekara Business Wire / AP Photo Biopharma companies are competing with tech giants to recruit data scientists and engineers. Here's how they can succeed. Read More Sponsor content by Atara Biotherapeutics Aiming to target the root cause of MS with an investigational off-the-shelf EBV T-cell immunotherapy Epstein-Barr virus (EBV) infects nearly 95% of adults by the age of 40, and while it can remain dormant in the body throughout life, new research suggests it can also drive serious diseases like multiple sclerosis (MS).ii, iii, vi, vii EBV-targeted cell-based immunotherapies may represent a novel investigational approach to treating MS. Opinion: I learned up close and personal about the necessity of improving diversity in clinical trials By Quita Highsmith Expanding the diversity of clinical trials is needed for many reasons, from improving the safety of new drugs to ensuring fairness. Read More Thursday, July 28, 2022       1 Exchange Pl, Suite 201, Boston, MA 02109 ©2022, All Rights Reserved. I no longer wish to receive STAT emails Update Email Preferences | Contact Us | View In Browser